Form 4: Vor Biopharma Director Granted 60,000 Stock Options

Vor Biopharma Director Sarah Burgess Reed was granted 60,000 stock options with an exercise price of $1.98, vesting monthly over three years, though she disclaims beneficial ownership.

Summary

• Director Sarah Burgess Reed received a grant of 60,000 stock options to purchase common stock.
• The stock options have an exercise price of $1.98 per share.
• Vesting for the options will occur in 36 successive equal monthly installments, commencing on September 8, 2025, contingent upon Ms. Reed's continued service.
• The options have an expiration date of September 7, 2035.
• Ms. Reed disclaims beneficial ownership of the options and underlying common stock, as they are held for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P., with proceeds offsetting advisory fees owed by the funds to RA Capital Management, L.P.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event, aligning management incentives with shareholder value. While the individual director disclaims direct beneficial ownership due to the RA Capital arrangement, it still represents a structured compensation and investment mechanism for a key stakeholder.

Positives

• The grant of 60,000 stock options to a director aligns their interests with the company's long-term performance, subject to vesting conditions.
• The options have a 10-year expiration period, providing a substantial long-term incentive for the director.

Negatives

• The reporting person disclaims beneficial ownership of the options and underlying common stock, as they are held for the benefit of RA Capital funds, which may reduce direct personal incentive for the individual director.

Risks

• NA

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook.

Management Comments

• NA

Industry Context

This transaction represents a routine equity grant to a director, a common practice in the biotechnology and pharmaceutical industry to incentivize leadership and align their interests with long-term shareholder value. It does not provide specific insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The reporting person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P., with the obligation to turn over any net cash or stock received to RA Capital Management, L.P. to offset advisory fees owed by the funds.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's long-term interests with shareholder value, although the direct personal financial incentive for the individual director is mitigated by the arrangement with RA Capital.
• RA Capital Funds: These funds are the ultimate beneficiaries of the option grant, as the proceeds will offset advisory fees, directly impacting their financial position.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director, which is a standard compensation practice. While it aligns the director's interests with the company's long-term performance, the disclaimer of direct beneficial ownership due to the RA Capital arrangement makes it less of a direct personal investment signal. It does not provide new information that would significantly alter the investment thesis for Vor Biopharma, thus a 'hold' recommendation is appropriate.

Keywords

Vor Biopharma, VOR, Stock Options, Director Compensation, Insider Transaction, Equity Grant, RA Capital, Biopharma